Treatment of dyslipidemias with DEAE-dextran
Barone, A.; Gaggi, S.; Pulido, M.E.; Pupita, F.
La Clinica Terapeutica 115(6): 469-475
1985
ISSN/ISBN: 0009-9074 PMID: 2420508 Document Number: 252303
Document emailed within 1 workday
Related Documents
Fedele, F. 2003: DEAE-Dextran in the treatment of primary hypercholesterolemia and/or hypercholesterolemia combined with hypertriglyceridemia. a multicentric randomized study on the efficacy of DEAE-Dextran compared with Cholestyramine La Clinica Terapeutica 154(4): 231-236Laithier, M.; Sheldrick, P. 1975: Influence of DEAE-dextran treatment and cellular "age" on infection by herpes simplex virus DNA Iarc Scientific Publications 1975(11 Part 1): 85-90
Pupita, F.; Barone, A.; Oliva, S.; Gaggi, S.; Pupita, G. 1986: Clinical pharmacology of DEAE-dextran. Metabolic and secondary effects in long-term treatment La Clinica Terapeutica 116(3): 171-178
Wittmann, G.; Bauer, K.; Mussgay, M. 1972: Trials of immunization of swine against foot-and-mouth disease using EEI-DEAE-Dextran vaccines Bulletin - Office International des Epizooties 77(5): 875-885
Hantschel, H.; Wagner, S. 1970: The effect of DEAE-dextran on the infectiousness of ribonucleic acid preparations of foot-and-mouth disease virus in various host systems Archiv für Experimentelle Veterinarmedizin 24(2): 473-480
Spalding, H.J.; Heath, T.J. 1991: Effects of the adjuvant DEAE-dextran and Staphylococcus aureus on the lymph pathways and filtering capacity of popliteal lymph nodes in sheep Research in Veterinary Science 51(1): 100-106
Evseeva, L.F.; Babaeva, E.E.; Kulberg, A.I. 1975: Comparative analysis of gamma globulin preparations isolated by means of DEAE-Sephadex and DEAE-cellulose Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 1: 88-90
Kihm, U. 1976: Comparison of a bivalent anti-foot-and-mouth disease vaccine with oil adjuvant to a vaccine with DEAE-dextran adjuvant in swine Developments in Biological Standardization 35: 149-153
Sobra, J. 1998: Screening and treatment of children and adolescents with hypercholesterolemias and dyslipidemias Casopis Lekaru Ceskych 137(3): 67-72
Bhoopalam, N.; Heller, P.; Meyerstein, N.; Hall, L. 1980: Effect of dextran-S (alpha, 1-3 dextran) on the growth of plasmacytomas MOPC-104E and J558 Journal of Immunology 125(4): 1454-1458
Salvati, E.A.; Lachiewicz, P. 1976: Thromboembolism following total hip-replacement arthroplasty. the efficicy of dextran-aspirin and dextran-warfarin in prophylaxis Journal of Bone and Joint Surgery. American Volume 58(7): 921-925
Simon, S.; Schönné, F.I. 1975: Kinetics of changes in dextran concentration in the blood of rabbits following administration of dextran preparations of various molecular weights Acta Pharmaceutica Hungarica 45(3): 120-127
Spoto, S.; Navajas Martinez, M.F.; Costantino, S. 2003: Dyslipidemias La Clinica Terapeutica 154(1): 65-69
Orlandi, F.; Serra, D. 1975: Dyslipidemias and hormones Minerva Medica 66(65): 3381-3387
Bucciante, G.; Bernardi, A. 1978: Obesity and dyslipidemias Giornale di Clinica Medica 59(7-8): 299-303
Pometta, D. 1989: Dyslipidemias and diabetes mellitus Journees Annuelles de Diabetologie de l'Hotel-Dieu 1989: 47-54
Knapp, W. 1974: Interactions of the third component of complement (C3) with cross-linked dextran. I. Binding of C3 from normal human serum to cross-linked dextran as defined by quantitative immunofluorescence Zeitschrift für Immunitatsforschung Experimentelle und Klinische Immunologie 148(3): 213-224
Poser, R.; Hirche, H. 1992: Randomized double-blind study of therapy of sudden deafness. Low molecular weight dextran + naftidrofuryl vs. low molecular weight dextran + placebo Hno 40(10): 396-399
Stevens, D.S.; Peeters-Asdourian, C. 1993: Treatment of postdural puncture headache with 'epidural dextran patch' Regional Anesthesia 18(5): 324-325
Eisner, M.; Grabowska, M.J.; Dobrohorska, H.; Nowotko, U. 1971: Possibility of erroneous evaluation of diabetes compensation during treatment with low-molecular dextran Polski Tygodnik Lekarski 26(51): 1982-1984